Literature DB >> 8738304

Electrophysiological studies of the cholecystokininA receptor antagonists SR27897B and PD140548 in the rat isolated nodose ganglion.

P M Beart1, E Krstew, R E Widdop.   

Abstract

With increased interest in the pharmacology of cholecystokininA (CCKA) receptors, including their trophic and mitogenic effects, the actions of two new non-peptide CCKA receptor antagonists, PD140548 and SR 27897B, were investigated in a convenient model system, the rat isolated nodose ganglion. CCK (1 nM-1 microM) caused concentration-dependent depolarisations when superfused over the nodose ganglion at 37 degrees C as measured by a silicone grease gap technique, and both CCKA antagonists caused significant rightward shifts in the concentration response curve to CCK. SR 27897B (3 and 10 nM) caused 7.9- and 17.9-fold shifts in the CCK concentration-response curve and the apparent-log KB values for each concentration of antagonist were calculated to be 9.36 and 9.23. Further experiments with PD140548 (30 and 100 nM) yielded shifts of 2.9- and 12.5-fold from which -log KB values were determined to be 7.80 and 8.06. Overall SR 27897B was significantly more efficacious than PD140548. Thus, the isolated nodose ganglion preparation allows a functional assessment of CCKA-mediated responses, with the results indicating that both SR 27897B and PD140548 are efficacious CCKA receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8738304     DOI: 10.1007/bf00167190

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  20 in total

1.  Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists.

Authors:  P R Boden; M Higginbottom; D R Hill; D C Horwell; J Hughes; D C Rees; E Roberts; L Singh; N Suman-Chauhan; G N Woodruff
Journal:  J Med Chem       Date:  1993-03-05       Impact factor: 7.446

2.  Multiple neuropeptides mobilise calcium in small cell lung cancer: effects of vasopressin, bradykinin, cholecystokinin, galanin and neurotensin.

Authors:  P J Woll; E Rozengurt
Journal:  Biochem Biophys Res Commun       Date:  1989-10-16       Impact factor: 3.575

3.  Cholecystokinin receptor binding in brain and pancreas: regulation of pancreatic binding by cyclic and acyclic guanine nucleotides.

Authors:  R B Innis; S H Synder
Journal:  Eur J Pharmacol       Date:  1980-07-11       Impact factor: 4.432

4.  CCK-A antagonists: which and how.

Authors:  M D'Amato; L C Rovati
Journal:  Eur J Clin Invest       Date:  1995-03       Impact factor: 4.686

Review 5.  Cholecystokinin stimulates Ca2+ mobilization and clonal growth in small cell lung cancer through CCKA and CCKB/gastrin receptors.

Authors:  T Herget; T Sethi; S V Wu; J H Walsh; E Rozengurt
Journal:  Ann N Y Acad Sci       Date:  1994-03-23       Impact factor: 5.691

6.  Membrane and action potential characteristics of A and C nodose ganglion cells studied in whole ganglia and in tissue slices.

Authors:  R Gallego; C Eyzaguirre
Journal:  J Neurophysiol       Date:  1978-09       Impact factor: 2.714

7.  Role of cholecystokinin in regulation of gastrointestinal motor functions.

Authors:  B M Meyer; B A Werth; C Beglinger; P Hildebrand; J B Jansen; D Zach; L C Rovati; G A Stalder
Journal:  Lancet       Date:  1989-07-01       Impact factor: 79.321

8.  Autoradiographic Localization of Cholecystokinin A and B Receptors in Rat Brain Using [125I]d-Tyr25 (Nle28,31)-CCK 25 - 33S.

Authors:  M. Carlberg; A. L. Gundlach; L. D. Mercer; P. M. Beart
Journal:  Eur J Neurosci       Date:  1992       Impact factor: 3.386

Review 9.  Cholecystokinin and gastrointestinal cancer.

Authors:  C B Lamers; J B Jansen; R A Woutersen
Journal:  J Steroid Biochem Mol Biol       Date:  1990-12-20       Impact factor: 4.292

10.  Cholecystokinin inhibits gastric motility and emptying via a capsaicin-sensitive vagal pathway in rats.

Authors:  H E Raybould; Y Taché
Journal:  Am J Physiol       Date:  1988-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.